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Abstract
In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII)
deficiency, patients received either agent at 30 mg/kg, intravenously per week for 4 weeks, in a randomized fashion. The primary
aim was to compare FVII:coagulation activity (FVII:C), 20 minutes after recombinant activated FVII (rFVIIa) injection, in the 2
groups. A secondary measure was self-reported bleeding. The median interquartile baseline range of the plasma level of activated
FVII (FVIIa) activity in the 2 groups was 1.6 (1.1-14.0) IU/dL and 5.0 (1.1-25.5) IU/dL. All patients achieved levels of FVIIa (FVII:C)
>30 IU/dL, 20 minutes after the injection of rFVIIa. Bleeding was similar between the 2 groups, with a comparable decrease in
severity and frequency compared to the last month prior to treatment. AryoSeven is similar to NovoSeven in increasing post-
injection FVIIa activity as well as in clinical safety and efficacy.
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Introduction
The availability of recombinant activated factor VII (rFVIIa)
has changed the management of bleeding in patients with con-
genital disorders, such as congenital factor VII (FVII) defi-
ciency, hemophilia A/B with an inhibitor, and Glanzmann
thrombasthenia.1-4 Coagulation FVII deficiency is a rare auto-
somal recessive hereditary disease caused by mutations in the
FVII gene on chromosome 13, affecting both males and
females.2-8 It has wide phenotypic and genotypic variability
similar to other hereditary bleeding disorders, for example, fac-
tor XI and factor VIII deficiency.9-13 The incidence of the dis-
ease is about 1 of every 500 000 people worldwide but is
significantly higher in countries such as Iran where interfamily
marriages are more common.8,14 According to the transplant
and special diseases office in Iran, and also Iranian comprehen-
sive Hemophilia care center (ICHCC) data registry, 7128
patients are registered with hereditary bleeding disorder and
232 patients have a congenital FVII deficiency.15
Coagulation FVII is naturally produced in the liver, with
the plasma level approximately 0.5 mg/mL in healthy
individuals,2,16 and only 1% of total FVII is in the activated
form in a normal person (FVIIa, 10-100 pmol/L).3,17 Since
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the binding of FVII to tissue factor is required to trigger the
extrinsic coagulation cascade, the lack of this factor reduces
the generation of thrombin that is required to activate plate-
lets, this results in inadequate production of fibrin. In
patients with severe FVII deficiency, lethal bleeding occurs
within a short time after birth and neonatal death may
occur.18 There is poor correlation between phenotypic mani-
festation and genotype and also between the plasma FVII:coa-
gulation activity (FVII:C) level and bleeding severity.7-14
Clinical manifestations can range from mild, such as mucosal
bleeding, to severe such as cerebral hemorrhage and abnormal
perioperative bleeding.13,14,16-19 Bleeding in infants usually
affects the central nervous system and is associated with
adverse effects.18
Recombinant FVIIa is a replacement therapy in patients
with congenital FVII deficiency and is used for the treatment
of bleeding episodes and prevention of bleeding during surgery
and other invasive procedures in these patients.14,16-19 Since
FVII deficiency is a rare bleeding disorder, there are few guide-
lines for management of bleeding episodes and prevention of
hemorrhagic events.18-20
In July 2005, NovoSeven received Food and Drug Adminis-
tration approval for use in congenital FVII deficiency bleeding
episodes.20,21
AryoSeven is designed as a biosimilar molecule of NovoSe-
ven. In this study, we compared therapeutic effects, side effects,
and safety between rFVIIa product AryoSeven and NovoSeven
in patients with congenital FVII deficiency.
Patients and Methods
Trial Design
This trial was a double-blinded, randomized, multi-center
study in 8 comprehensive hemophilia care centers around
Iran. Eligible patients who met inclusion criteria were rando-
mized between 2 treatment groups (group A: Aryoseven as the
intervention group, group B: Novoseven as the control group).
Randomization was based on consecutive balanced block ran-
domization tables that were assigned separately for each study
site. We designed a form to collect patients’ data including
demographic information, medical history, physical examina-
tion, and laboratory results for the study. The randomized
patients received 1 single dose of rFVIIa (Aryoseven in group
A or Novoseven in group B) 30 mg/kg, intravenously, once a
week for 4 consecutive weeks as prophylaxis.22-24 A total of
66 patients were enrolled in the trial and there was no with-
drawal during the study (group A: 35 patients and group B:
31 patients).
The patients’ visits included 6 visits for each patient that
consisted of a screening visit (visit 1), 4 weekly visits (visits
2-5), and 1 follow-up visit (visit 6).
Bleeding Severity Assessment
The patients were assessed for bleeding severity which was
classified from mild to severe at each center by 1 physician
with prepared form. Mild bleeding was defined as bruising,
hemorrhoid bleeding, microscopic hematuria, and situations
considered being part of everyday life which did not interfere
with daily activities nor requires medical attention. Moderate
bleeding was clinically overt but not meeting criteria for severe
bleeding. Severe bleeding was defined as clinically overt bleed-
ing associated with a drop in hemoglobin more than 2 g/dL or
requiring blood transfusion more than 2 units of red blood cells,
retroperitoneal or intracranial bleeding.25,26
Ethical Consideration
This study was approved by the ethics committee of the Iranian
Blood Transfusion Organization and the Ministry of Health in
agreement with Declaration of Helsinki and good clinical prac-
tice. The trial was registered on the IRCT Web site with regis-
tration number: 201104266302N1.
Patient Eligibility
Inclusion criteria consisted of patients with congenital FVII
deficiency and more than 1 episode of bleeding per month and
age >2 years. All patients included in study had lower than 30
IU/dL of FVII:C. Exclusion criteria included any other coagu-
lation disease, previous prophylaxis therapy with rFVIIa during
the past month, platelet count <50 000, presence of a neutraliz-
ing anti-FVII antibody, and a history of severe atherosclerosis.
Patients met inclusion criteria by scientific committee of
clinical trial team eligible for study. Written informed consent
was signed by all patients or their legal guardians.
Laboratory Methods
FVII coagulation activity was measured by 1-stage clotting
method using recombinant-tissue factor preparation (STA-
Deficient and STA-Neoplastin; Diagnostica Stago, France).
Factor VII inhibitor was measured by classic ‘‘Bethesda assay’’
and the inhibitor titer reported in ‘‘Bethesda Unit.’’
Outcomes and Safety
The primary outcome was the level of plasma FVII:C activity
20 minutes after rFVIIa injection, with a level of FVII: C <30
IU/dL considered a treatment failure. Secondary outcome
measures were self-reported incidence of bleeding or severity
and frequency of side effects and adverse events. Treatment
safety was analyzed by evaluation of adverse events reported
throughout the study period until 3 months after the fourth
injection.
Statistical Analysis
Participants’ data were collected in the Case Report Forms
(CRF) during the study and their accuracy was monitored by
study supervisor to ensure their adherence to study protocol.
Data were analyzed by SPSS software (version 16.0, SPSS
Co, Chicago, Illinois) and were described based on their
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statistical analysis. Quantitative data were expressed as mean
+ standard deviation and qualitative data were expressed as
frequency and proportion (percentage). The FVII plasma levels
(FVII:C) did not exhibit a normal distribution, therefore the
variation was presented as median and interquartile range
(IQR). Quantitative data comparing the study group and the
control group were analyzed using a parametric t test for data
with normal distribution and nonparametric Mann-Whitney U
test for data with an abnormal distribution (FVII:C plasma lev-
els and rates of change during treatment). Independent qualita-
tive data were analyzed by chi-square test and if it was
necessary the Fisher exact test and dependent qualitative data
were analyzed by McNemar test. The standard level of statisti-
cal significance was considered to be P  .05.
Results
The mean age of the patients in the study was 21.8 + 15.7
years (range: 2-65 years) and a total of 66 patients (33 male
and 33 female) were enrolled in this study. The comparison
of baseline data between 2 groups regarding age, sex, and
FVII:C plasma levels did not show any significant difference
(Table 1). Other factors, such as vital signs (respiratory rate,
heart rate, blood pressure, and body temperature), coagulation
tests (prothrombin time and partial thromboplastin time), liver
and renal function tests, and blood count were not signifi-
cantly different between the 2 groups. Median IQR plasma
levels of FVIIa activity (FVII:C) in groups A and B were
1.6 (1.1-14.0) IU/dL and 5.0 (1.1-25.5) IU/dL, respectively,
before injection (Table 1). All patients achieved target levels
of FVII:C. All patients in both the groups had levels of FVII:C
>30 IU/dL, 20 minutes after rFVIIa injection; therefore, there
were no treatment failures. The increased levels of FVII:C
were comparable between the 2 groups. There was no differ-
ence in levels of FVII:C 20 minutes after rFVIIa injection
between the 2 groups in each of the 4 weeks of treatment
(Table 2).
The results also showed that the distribution of changes in
FVII:C plasma levels after rFVIIa injection at the critical cutoff
point (percentile 20) was similar between the 2 groups (Table 3).
The 20th percentile was chosen because 80% of patients had
increase over the amount of the serum levels of FVII in each
treatment group and each week. So the comparison between
the cutoff points help us to the better understand their perfor-
mance relative to each other.
The change in severity of bleeding was similar between the
2 groups, with a similar reduction in bleeding observed after
treatment compared to before treatment of rFVIIa (Table 4).
The change in frequency of monthly bleeding episodes was
also similar between the 2 groups, with a similar reduction
compared to the baseline (reduction in median of bleeding fre-
quency during the month of treatment in group A and group B
was 1 [IQR: 1-2] per month, P ¼ .626; Table 4).
Reported side effects were minor (headache, nausea) and
occurred at a similar frequency in both the groups (group A:
8 [22.9%] and group B: 3 [9.7%]). The frequency of side effects
is presented in Table 5. No severe side effects were observed
during the study period and up until 3 months after the fourth
rFVIIa injection
Discussion
A comparative clinical trial was undertaken to establish the
biosimilar effects of rFVIIa (AryoSeven) to NovoSeven in
terms of quality and clinical efficacy. The present study
intended to elucidate the noninferiority of AryoSeven in com-
parison to NovoSeven in increasing the FVII level (FVII:C)
Table 1. Comparison of Baseline Characteristics in the 2 Treatment
Groups.
Variable
Group A:
AryoSeven;
n ¼ 35
Group B:
NovoSeven;
n ¼ 31
P
Value
Age (mean+ SD) years 24.6+ 16.3 18.6+ 14.7 .122
Sex, M/F 16/19 17/14 .459
Factor VII, IU/dL (med [IQR]) 1.6 (1.1-14.0) 5.0 (1.1-25.5) .346
Bleeding frequency during the
last month (mean + SD)
1.74 + 1.67 1.87+ 1.46 .742
Bleeding severity
Mild 60.0% 51.6% .249
Moderate 34.3% 48.4%
Severe 5.7% 0.0%
Abbreviations: SD, standard deviation; M, male; F, female; med, median; IQR,
interquartile range.
Table 2. Comparison of Changes in Factor VII Plasma Level (FVII:C)
From Before to After rFVIIa Injection Between the 2 Groups.a,b
Difference
Between Before
and After
Group A:
AryoSeven;
n ¼ 35
Group B:
NovoSeven;
n ¼ 31
P
Value
Difference week 1 256.0 (198.4-379.0) 264.9 (179.0-560.0) .837
Difference week 2 207.6 (172.9-653.0) 226.0 (171.0-478.0) .979
Difference week 3 224.2 (187.0-425.1) 236.0 (175.0-491.4) .974
Difference week 4 220.1 (196.3-455.6) 224.0 (178.0-458.0) .581
Abbreviations: FVII:C, factor VII:coagulation activity; rFVIIa, recombinant acti-
vated FVII; IQR, interquartile range.
aAll units are in IU/dL.
bDepend on the kind of distribution, data are shown as median (IQR).
Table 3. Comparison of Distribution of Changes in Factor VII Level
Between Before and After rFVIIa Injection at the Critical Cut of Point
(Percentile 20) in the 2 Groups.
Difference Between
Before and After
Group A:
AryoSeven; n ¼ 35
Group B:
NovoSeven; n ¼ 31
Difference Week 1 190.8 175.4
Difference Week 2 158.4 167.6
Difference Week 3 175.8 169.2
Difference Week 4 172.0 158.9
Abbreviation: rFVIIa, recombinant activated FVII.
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and its clinical efficacy in prevention of bleeding events.
Some similarities exist between our findings and the previous
clinical trials designed for Novoseven. Baseline characteris-
tics were similar to other studies considering the range of age,
sex, bleeding severity, and FVII levels. In other studies, the
age range was between 1 and 45 years and 52% of patients
were female.2,27 The prophylactic dosages of rFVIIa in those
studies ranged from 30 to 90 mg/kg per week. In this study, a
dosage of 30 mg/kg per week was administered.21-24 The data
obtained in this study demonstrated a reduction in the number
of bleeding episodes and also bleeding severity in both treat-
ment groups when using the recommended dosage. The mean
level of FVII before intervention in other studies was between
1 and 20 IU/dL, which is similar to our findings.2-9 Factor VII
levels were increased to at least 50 IU/dL in the current study,
which was similar to previous trials.22-28 Thrombosis was
reported in some cases after injection of rFVIIa in other stud-
ies but we did not encounter any thrombosis among our
patients.28 Also similar to other studies, study patients did not
demonstrate any serious side effects and there was no signif-
icant difference between frequency of side effects.5,29
Based on the present data, this study demonstrates noninfer-
iority of AryoSeven compared to NovoSeven in controlling and
preventing bleeding episodes. The incidence of side effects
showed no significant differences between 2 groups.
Although the therapeutic advances in control of bleeding
episodes have led to a decreased morbidity and a better quality
of life, the expense limits its access in some countries.15,28 Bio-
similar rFVIIa (AryoSeven) has similar activity with signifi-
cantly lower cost compared to NovoSeven. Access and
availability of treatment vary widely around the world.21 The
noninferiority of this drug at a significantly lower cost would
fulfill the World Federation of Hemophilia mission to find effi-
cient recombinant coagulation products at a reasonable price to
close the gap in care and achieve treatment for all.20,21
Conclusion
AryoSeven is similar to NovoSeven in postinjection FVIIa
activity as well as in clinical efficacy. The frequency of side
effects was also similar; however, the study was underpowered
to detect differences in rare complications between the 2 com-
pounds. The results of this study warrant additional clinical
investigations to demonstrate the similar clinical and safety
profile of AryoSeven in comparison to the branded
NovoSeven.
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Table 4. Comparison of Changes of Bleeding Severity and Frequency Between Before and After Treatment Period in the 2 Groups.
Postintervention
None Mild Moderate Severe Total P Value
Group A (AryoSeven)
Preintervention
None 0 0 0 0 0 (0.0%) .500
Mild 16 3 2 0 21 (60.0%)
Moderate 10 0 2 0 12 (34.3%)
Severe 2 0 0 0 2 (5.7%)
Total 28 (80.0%) 3 (8.6%) 4 (11.4%) 0 (0.0%) 35
Group B (NovoSeven)
Preintervention
None 0 0 0 0 0 (0.0%) .646
Mild 12 3 1 0 16 (51.6%)
Moderate 11 2 2 0 15 (48.4%)
Severe 0 0 0 0 0 (0.0%)
Total 23 (74.2%) 5 (16.1%) 3 (9.7%) 0 (0.0%) 31
Table 5. Side Effects Observed During Treatment of FVIIa.
Type of
Side Effect
Group A:
AryoSeven; n ¼ 35
Group B:
NovoSeven; n ¼ 31 P Value
Headache 3 1 .840
Arthralgia 1 0
Rash 1 1
Urticaria 1 1
Fever 1 0
Nausea 3 0
Local 1 1
Totala 11 4
None 27 (77.1%) 28 (90.3%)
Abbreviation: rFVIIa, recombinant activated FVII.
aSome patients reported more than one side effect.
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